This story carefully reports on these results, with appropriate caveats that emphasize the small size of the study, the preliminary nature of the results and narrow patient population (those with pre-cancerous lesions or early-stage cancer). It quotes several independent experts and discloses potential conflict of interest. The story could have been improved by mentioning the cost of the IUD and insurance coverage.
The progestin-containing IUD (brand name Mirena) is a highly effective, well-tolerated form of birth control. Pathology studies have also shown that the IUD can cause reversal of cellular changes, known as hyperplasia, in the lining of the uterus (enodmetrium) that could later lead to certain kinds of endometrial cancer.Oral progestins are an established treatment for endometrial hyperplasia and have also been used in some cases of endometrial cancer in younger women. Targeting progesterone release directly to the uterine lining through the IUD presents a potential advance in effectiveness and tolerability of treatment, while preserving fertility.
The primary treatment for endometrial cancer is hysterectomy, or surgical removal of the uterus. However, for some women, particularly younger women who wish to preserve their fertility, the idea of a non-surgical alternative, is welcome news. A small study was published in this week’s Annals of Oncology followed 20 women with hyperplasia and 14 women with early-stage endometrial cancer who had a progestin-IUD implanted. Almost all (95%) of those with hyperplasia experienced reversal, while about half (57%) of those with early-stage endometrial cancer did.
The story does not mention any costs of the IUD or other treatments.
The story quantifies the benefits of the progestin IUD in several ways.
The story accurately notes that the study reported no adverse effects. The study’s authors reported only on adverse effects that were sufficient to require suspension of treatment.
The story provides important details about the current study that help the reader evaluate the strength of the evidence. It even emphasizes that the new treatment approach is "still uNPRoven".
The story does not exaggerate the seriousness or prevalence of uterine cancer and is clear to point out that this treatment is only appropriate for a small subset of cases.
The story quotes several independent experts and notes that none had a conflict of interest.
The story compares the progestin IUD with systemic hormones and hysterectomy
The progestin IUD is clearly available.
The story clearly states that the Mirena IUD is not a new idea, but using it to treat early-stage endometrial cancer is relatively novel.
Because the story quotes several independent experts, the reader can assume that the story did not rely on a press release as the sole source of information.
Systematic, Criteria-Driven
Monday at #ADA2021, an infectious disease epidemiologist, a journalist, and a researcher shared perspectives on communication of risk in the era of COVID-19: http://ow.ly/ROfR30rMeE7 @AstleyCM @garyschwitzer @berthahidalgo @ADA_DiabetesPro
Shoutouts to @susan_bewley @drkevinknopf @MichaelBaum11 in this call for more than fawning coverage from press releases for these kinds of stories.
Also, linked history inside goes back 5 years just on Grail apparently trying to become Holy Grail. https://twitter.com/garyschwitzer/status/1408849696416841731
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like